COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #117
Source   PDF   Share   Tweet
See all 181 studies
9/2
Inconc.
Pre-Exposure Prophylaxis study (treated before exposed to the virus)
de la Iglesia et al., medRxiv, doi:10.1101/2020.08.31.20185314 (Preprint)
Hydroxicloroquine for pre-exposure prophyylaxis for SARS-CoV-2
Analysis of autoimmune disease patients on HC Q, compared to a control group from the general population (matched on age and sex, but not adjusted for autoimmune disease), showing non-significant differences between groups.
Other research shows that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, Ferri et al. show OR 4.42, p<0.001 [1], which is the observed real-world risk, taking into account factors such as these patients potentially being more careful to avoid exposure.
If we adjust for the different baseline risk, the mortality result becomes RR 0.35, p=0.23, suggesting a substantial benefit for HC Q treatment (as shown in other studies).
hospitalization, ↑50.0%, p=1.00
COVID-19 case, ↑42.6%, p=0.15, suspected COVID-19
COVID-19 case, ↓7.8%, p=0.84, confirmed COVID-19
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.
Submit